ZLZhiguo Luo

Zhiguo Luo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhiguo Luo has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Li Shen

    Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China

    5 shared publications
  • Feng Peng

    Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China

    4 shared publications
  • Li Qiu

    Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, PR China

    4 shared publications
  • Bingbing Tang

    Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medicine, Hubei University of Medicine, Shiyan 442000, China

    3 shared publications
  • Chuanyi Zhang

    Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China

    3 shared publications
  • Xiaoxia Dong

    Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, China

    3 shared publications

Latest Publications

  • A highly sensitive ESIPT fluorescent probe for visualization of HK2-mediated lung cancer progression via imaging nitroreductase

    by Miao Chen, Kelong Wang, Han Zhang, Bingbing Tang, Yiqin Qu, Jinfeng Luan, Ming Luo, Haixia Li, Chao Luo, Zhiguo Luo, et al.


  • Small-molecule fluorescent probes for imaging intracellular amyloid toxicity induces ferroptosis via HClO fluctuation in Alzheimer's disease

    by Wenhui Ma, Bingbing Tang, Han Zhang, Yixin Qu, Jinfeng Luan, Kelong Wang, Wenbo Chen, Xijuan Wang, Xinran Liu, Hongyan Zhao, et al.


  • GALNT14-mediated O-glycosylation drives lung adenocarcinoma progression by reducing endogenous reactive oxygen species generation

    by Bingbing Tang, Kelong Wang, Qiulei Ren, Junshuo Zhou, Yuewen Xu, Liaoyuan Liu, Bin Yin, Yaling Zhang, Qian Huang, Ruiqi Lv, et al.


  • Open Access

    A novel mechanism for C1GALT1 in the regulation of gastric cancer progression

    by Xiaoxia Dong, Chunli Chen, Xinzhou Deng, Yongyu Liu, Qiwen Duan, Zhen Peng, Zhiguo Luo, Li Shen

    Background: Gastric cancer (GC) is a highly aggressive and lethal disease around the world. High expression of core 1 β 1, 3-galactosyltransferase 1 (C1GALT1), the primary enzyme responsible for protein O-glycosylation, plays a critical role in gastric carcinogenesis. However, proteins that can be O-glycosylated by C1GALT1 in GC have not been completely elucidated. Also, the mechanism leading to its upregulation in GC is currently unknown. Results: Using public databases and our patient samples, we confirmed that C1GALT1 expression was upregulated at both the mRNA and protein levels in GC tissues. Elevated expression of C1GALT1 protein was closely associated with advanced TNM stage, lymph node metastasis, tumor recurrence, and poor overall survival. With gain- and loss-of-function approaches, we demonstrated that C1GALT1 promoted GC cell proliferation, migration, and invasion. By employing lectin pull-down assay and mass spectrometry, integrin α5 was identified as a new downstream target of C1GALT1 in GC. C1GALT1 was able to modify O-linked glycosylation on integrin α5 and thereby modulate the activation of the PI3K/AKT pathway. Functional experiments indicated that integrin α5 inhibition could reverse C1GALT1-mediated tumor growth and metastasis both in vitro and in vivo. Moreover, transcription factor SP1 was found to bind to the C1GALT1 promoter region and activated its expression. Further investigation proved that miR-152 negatively regulated C1GALT1 expression by directly binding to its 3′ -UTR. Conclusions: Our findings uncover a novel mechanism for C1GALT1 in the regulation of GC progression. Thus, C1GALT1 may serve as a promising target for the diagnosis and treatment of GC.


  • A lectin-based glycomic approach identifies FUT8 as a driver of radioresistance in oesophageal squamous cell carcinoma

    by Li Shen, Min Xia, Xinzhou Deng, Qing Ke, Chuanyi Zhang, Feng Peng, Xiaoxia Dong, Zhiguo Luo

    Purpose Radio-resistance is recognized as a main factor in the failure of radiotherapy in oesophageal squamous cell carcinoma (ESCC). Aberrant cell surface glycosylation has been reported to correlate with radio-resistance in different kinds of tumours. However, glycomic alterations and the corresponding enzymes associated with ESCC radio-resistance have not yet been defined. Methods Two radioresistant cell lines, EC109R and TE-1R, were established from parental ESCC cell lines EC109 and TE-1 by fractionated irradiation. A lectin microarray was used to screen for altered glycan patterns. RNA-sequencing (RNA-seq) was employed to identify differentially expressed glycosyltransferases. Cell Counting Kit-8, colony formation and flow cytometry assays were used to measure cell viability and radiosensitivity. Expression of glycosyltransferase in ESCC tissues was assessed by immunohistochemistry. In vivo radiosensitivity was analysed using a nude mouse xenograft model. Downstream effectors of the enzyme were verified using a lectin-based pull-down assay combined with mass spectrometry. Results We found that EC109R and TE-1R cells were more resistant to irradiation than the parental EC109 and TE-1 cells. Using lectin microarrays combined with RNA sequencing, we found that α1, 6-fucosyltransferase (FUT8) was overexpressed in the radioresistant ESCC cell lines. Both gain- and loss-of-function studies confirmed that FUT8 regulates the sensitivity of ESCC cells to irradiation. Importantly, we found that high FUT8 expression was positively linked to radio-resistance and a poor prognosis in ESCC patients who received radiation therapy. Moreover, FUT8 inhibition suppressed the growth and formation of xenograft tumours in nude mice after irradiation. Using a lectin-based pull-down assay and mass spectrometry, we found that CD147 could be glycosylated by FUT8. As expected, inhibition of CD147 partly reversed FUT8-induced radio-resistance in ESCC cells. Conclusions Our results indicate that FUT8 functions as a driver of radio-resistance in ESCC by targeting CD147. Therefore, FUT8 may serve as a marker for predicting the response to radiation therapy in patients with ESCC.


  • PAG1 promotes the inherent radioresistance of laryngeal cancer cells via activation of STAT3

    by Li Shen, Qing Ke, Jingjing Chai, Chuanyi Zhang, Li Qiu, Feng Peng, Xinzhou Deng, Zhiguo Luo


  • β3GnT8 regulates oxaliplatin resistance by altering integrin�β1 glycosylation in colon cancer cells

    by Li Shen, Xiaoxia Dong, Yingying Wang, Li Qiu, Feng Peng, Zhiguo Luo

    Correlations between drug resistance and glycosylation changes have been analyzed intensively in the field of tumor biology. The present study was aimed to investigate the glycan and glycogene alterations involved in oxaliplatin resistance in human colon cancer cells. Using the lectin micro-array for glycan composition and FITC-lectin binding for glycan profiling, we found that polylactosamine-type N-glycans were significantly increased in oxaliplatin-resistant SW620R cells. Using real-time PCR for quantification of glycogenes, we targeted beta-1,3-N-acetylglucosaminyltransferase 8 (beta 3GnT8), which was overexpressed in SW620R cells. Using an RNA interference strategy, we revealed that the silencing of beta 3GnT8 in SW620R cells resulted in increased chemosensitivity to oxaliplatin. Conversely, the engineered overexpression of beta 3GnT8 in SW620 cells enhanced resistance to oxaliplatin. Further data revealed that manipulation of beta 3GnT8 was able to modify polylactosamine chains on integrin beta 1 and to regulate the integrin beta 1 downstream signaling pathway. These results revealed that beta 3GnT8 may play a key role in the development of oxaliplatin resistance in colon cancer cells possibly through the alteration of the glycosylation of integrin beta 1. These findings may be valuable for overcoming drug resistance in colon cancer.


  • Open Access

    Knockdown of C1GalT1 inhibits radioresistance of human esophageal cancer cells through modifying β1-integrin glycosylation

    by Chuanyi Zhang, Xinzhou Deng, Li Qiu, Feng Peng, Shanshan Geng, Li Shen, Zhiguo Luo

    Radiotherapy has played a limited role for the treatment of human esophageal cancer owing to the risk of tumor radioresistance. Core 1 β1, 3-galactosyltransferase (C1GalT1), which catalyzes the formation of core 1 O-glycan structures, is frequently overexpressed during tumorigenesis. However, the exact effects and mechanisms of C1GalT1 in the radioresistance of esophageal cancer remain unclear. In this study, Public databases and our data revealed that C1GalT1 expression was up-regulated in esophageal cancer tissues and was associated with poor survival. Upon irradiation, we found that esophageal cancer cells with high levels of C1GalT1 could tolerate cell death and had increased resistance to radiotherapy. Irradiation also promoted the expression of C1GalT1 and core 1 O-glycan structures. C1GalT1 knockdown increased the radiosensitivity of esophageal cancer cells, and attenuated irradiation-enhanced migration and invasion. Mechanistic investigations showed that C1GalT1 modified O-glycan structures on β1-integrin and regulated its downstream focal adhesion kinase (FAK) signaling. Furthermore, β1-integrin-blocking antibody and FAK inhibitor enhanced radiation-induced apoptosis in esophageal cancer cells. Together, our results indicate that C1GalT1 is a major determinant of radioresistance via modulation of β1-integrin glycosylation. C1GalT1 may be a potent molecular target for enhancing the efficacy of radiotherapy.


  • Open Access

    β3GnT8 Promotes Gastric Cancer Invasion by Regulating the Glycosylation of CD147

    by Li Shen, Xiaoxia Dong, Meiyun Yu, Zhiguo Luo, Shiliang Wu

    β1, 3-N-acetylglucosminyltransferase 8(β3GnT8) synthesizes a unique cabohydrate structure known as polylactosamine, and plays a vital role in progression of various human cancer types. However, its involvement in gastric cancer remains unclear. In this study, we analyzed the expression and clinical significance of β3GnT8 by Western blot in 6 paired fresh gastric cancer tissues, noncancerous tissues and immunohistochemistry on 110 paraffin-embedded slices. β3GnT8 was found to be over-expressed in gastric cancer tissues, which correlated with lymph node metastasis and TNM stage. Forced the expression of β3GnT8 promoted migration and invasion of gastric cancer cells, whereas β3GnT8 knockdown led to the opposite results. Further studies showed that the regulated β3GnT8 could convert the heterogeneous N-glycosylated forms of CD147 and change the polylactosamine structures carried on CD147. In addition, our data suggested the annexin A2 (ANXA2) to be an essential interaction partner of β3GnT8 during the process of CD147 glycosylation. Collectively, these results provide a novel molecular mechanism for β3GnT8 in promotion of gastric cancer invasion and metastasis. Targeting β3GnT8 could serve as a new strategy for future gastric cancer therapy.


  • Radiosensitisation of human glioma cells by inhibition of β1,6-GlcNAc branched N-glycans

    by Li Shen, Xiao-Xia Dong, Jun-Bo Wu, Li Qiu, Qi-Wen Duan, Zhi-Guo Luo

    Gliomas are the most prevalent type of primary brain tumors and are resistant to radiation therapy. β1,6-GlcNAc branched N-glycans, which are encoded by N-acetylglucosaminyltransferase V (GnT-V), play important roles in glioma progression. However, the relationship between β1,6-GlcNAc branched expression and radiosensitivity in glioma cells is still unknown. In this study, the expression of β1,6-GlcNAc branched N-glycans in nonneoplastic brain and glioma samples was characterized by lectin histochemistry. The radiosensitivity of glioma cells was evaluated by colony formation assay. We found that β1,6-GlcNAc branches were highly expressed in glioblastoma specimens, compared with diffuse astrocytomas and nonneoplastic brain. In addition, β1,6-GlcNAc branched expression was negatively correlated with the radiosensitivity of glioblastoma cells. Furthermore, the inhibition of N-linked β1,6-GlcNAc branches by GnT-V silencing in U251 cells could reduce the cell clonogenic survival after X-irradiation. Meanwhile, the G2/M checkpoint was impaired and there was an increase in the number of apoptotic cells. Tunicamycin, an inhibitor of N-glycan biosynthesis, was also able to enhance the radiosensitivity of U251 cells. Thus, our results suggest that development of therapeutic approaches targeting N-linked β1,6-GlcNAc branches may be a promising strategy in glioblastoma treatment.